Comparison of congenital malformations among babies born after administration of letrozole or clomiphene citrate for infertility treatment in a Korean cohort.

Abstract

This retrospective study investigated and compared the incidence of congenital foetal anomalies after letrozole versus clomiphene citrate (CC) administration for infertility treatment. Data from 142 newborns were included: letrozole group, n = 83; CC group, n = 61. Congenital anomalies were found in 7.2% (6/83) patients in the letrozole group and 18.0% (11/61) patients in the CC group, with no significant between-group difference (p = .066). Major congenital anomaly rate was 2.4% (2/83) in the letrozole group and 3.3% (2/61) in the CC group, with no significant between-group difference (p > 0.999). There was no significant difference in major and minor congenital anomalies between the groups after excluding premature infants (birth at a gestational age of <37 weeks), low birth weight, and very low birth weight. The results of this study demonstrate the stability of letrozole compared to that of CC for infertility treatment in pregnant women.

• Authors: Jisun Yun, Young Sik Choi, Inha Lee, Young Bin Won, Jae Hoon Lee, Seok Kyo Seo, SiHyun Cho, Byung Seok Lee, Bo Hyon Yun
• Journal: Reproductive toxicology (Elmsford, N.Y.) (Reprod Toxicol) Vol. 82 Pg. 88-93 (12 2018) ISSN: 1873-1708 [Electronic] United States
• PMID: 30339890 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Aromatase Inhibitors
• Fertility Agents, Female
• Clomiphene
• Letrozole

Topics

• Adult
• Aromatase Inhibitors (therapeutic use)
• Asian People
• Clomiphene (therapeutic use)
• Cohort Studies
• Congenital Abnormalities (epidemiology)
• Female
• Fertility Agents, Female (therapeutic use)
• Humans
• Infant, Newborn
• Infertility, Female (drug therapy)
• Letrozole (therapeutic use)
• Male